KRAS and lung cancer: Another in vitro study showed the effectiveness of HSP90 inhibition in several KRAS‐mutated non‐small cell lung cancer (NSCLC) lines by ganetespib – a non‐geldanamycin analog with less toxic side effects (Acquaviva et al., 2012).